Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VIP

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: VIP. Displaying page 1 of 1.
    EudraCT Number: 2009-011088-35 Sponsor Protocol Number: PACAMUS Start Date*: 2010-03-24
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAM...
    Medical condition: Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive int...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004943-31 Sponsor Protocol Number: 21 March, 2007 Start Date*: 2007-10-03
    Sponsor Name:Centre of Thrombosis and Haemostasis
    Full Title: The VWD International Prophylaxis (VIP) Study
    Medical condition: Severe form of von Willebrand disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005504-17 Sponsor Protocol Number: STOGVIP01 Start Date*: 2013-03-21
    Sponsor Name:Institute of oncology
    Full Title: VINCRISTINE OR CIS-PLATIN, BOTH IN COMBINATION WITH GEMCITABINE OR PEMETREXED FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER – VIP TRIAL
    Medical condition: advanced non small cell lung cancer in patients over seventy years old
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001895-72 Sponsor Protocol Number: Version1.0 Start Date*: Information not available in EudraCT
    Sponsor Name:Västerbottens läns landsting
    Full Title: VIP-VIZA intensive multimodal cardiovascular intervention sub-study - a phase 2 randomized controlled trial
    Medical condition: Cardiovascular disease - established artherosclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021951-26 Sponsor Protocol Number: UoL000621/R&D3963 Start Date*: 2011-04-15
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Royal Liverpool and Broadgreen University Hospitals Trust
    Full Title: VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or m...
    Medical condition: Locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003336-37 Sponsor Protocol Number: HBA_001 Start Date*: 2018-06-25
    Sponsor Name:SGHL – SOCIEDADE GESTORA DO HOSPITAL DE LOURES, S.A - Hospital Beatriz Ângelo
    Full Title: CA2209-9G7: Phase II multi-institutional proof of concept single-arm trial of Nivolumab in the treatment of patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors
    Medical condition: Metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001132-19 Sponsor Protocol Number: 1-10-72-67-17 Start Date*: 2017-07-04
    Sponsor Name:Aarhus University Hospital
    Full Title: Effects of Metformin on portal hypertension in patients with cirrhosis.
    Medical condition: cirrhosis and portal hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10036201 Portal hypertensions HLT
    20.0 100000004871 10009211 Cirrhosis liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003621-24 Sponsor Protocol Number: MG-101-01 Start Date*: 2008-05-29
    Sponsor Name:MondoGEN AG
    Full Title: Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Pe...
    Medical condition: Pulmonary arterial hypertension (PAH) due to idiopathic pulmonary arterial hypertension (IPAH), familial PAH or PAH associated with connective tissue diseases (CTD) (e.g. systemic sclerosis, system...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    9.1 10065151 Idiopathic pulmonary arterial hypertension LLT
    9.1 10065152 Familial pulmonary arterial hypertension LLT
    9.1 10065150 Associated with pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000661-16 Sponsor Protocol Number: CGRP2020 Start Date*: 2020-06-18
    Sponsor Name:Rigshospitalet Glostrup
    Full Title: The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002670-40 Sponsor Protocol Number: NL44913.029.13 Start Date*: 2015-09-09
    Sponsor Name:VU University Medical Center (VUmc)
    Full Title: Noninvasive Imaging of Vulnerable Inflammatory Coronary Plaque using Cardiac PET/CT in Humans: a feasibility study
    Medical condition: The IMP (PET-tracer) will be investigated in patients 24-72 hours after an acute coronary syndrome without excessive enzyme release (CK < 180 U/L) during PET scanning protocol.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10066521 Coronary artery disease progression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001378-19 Sponsor Protocol Number: A5031003 Start Date*: 2004-09-28
    Sponsor Name:Pfizer AB
    Full Title: A two part study to a) investigate the reproducilibility of the vaginal photoplethysmograhpy (VPP) teqnique in healthy pre-menopausal volunteers and subjects suffering from Female Sexual Arousal Di...
    Medical condition: Female Sexual Arousal Disorder (FSAD)
    Disease: Version SOC Term Classification Code Term Level
    10062641
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001379-20 Sponsor Protocol Number: A5031004 Start Date*: 2004-09-28
    Sponsor Name:Pfizer AB
    Full Title: A two part study to a) investigate the reproducibility of the vaginal photoplethysmography (VPP) technique in healthy post-menopausal volunteers and subjects suffering from Female Sexual Arousal Di...
    Medical condition: Female Sexual Arousal Disorder (FSAD)
    Disease: Version SOC Term Classification Code Term Level
    10062641
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2023-000061-14 Sponsor Protocol Number: BCN04-DASA Start Date*: 2023-05-26
    Sponsor Name:Institut de Recerca Germans Trias i Pujol
    Full Title: Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People with HIV under Antiretroviral Treatment
    Medical condition: Human immunodeficiency virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004536-29 Sponsor Protocol Number: CHUBX2017/44 Start Date*: 2022-12-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Efficacy and tolerance of the association of MTX and phototherapy versus phototherapy in adults with progressive vitiligo : a randomized double blind prospective study (METVI)
    Medical condition: Progressive vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001598-10 Sponsor Protocol Number: PB1046-PT-CL-0004 Start Date*: 2020-01-24
    Sponsor Name:PhaseBio Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adu...
    Medical condition: Symptomatic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004904-35 Sponsor Protocol Number: Protocol2-55-52030-726 Start Date*: 2006-08-14
    Sponsor Name:IPSEN PHARMA S.A.S.
    Full Title: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg ...
    Medical condition: Non functioning entero-pancreatic tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Completed) CZ (Completed) GR (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006819-75 Sponsor Protocol Number: CRAD001C2324 Start Date*: 2007-10-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine t...
    Medical condition: Pancreatic neuroendocrine tumors (also called pancreatic endocrine tumors or islet cell tumors (ICT))
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) GR (Completed) BE (Completed) GB (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 18:55:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA